Brief cognitive behavioral therapy appears promising for head and neck cancer survivors with body-image distress

Rybrevant Faspro combination demonstrates 77% ORR in first-line treatment of advanced head and neck cancer, phase II study finds

First-line subcutaneous Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) plus a PD-1 inhibitor and fixed-duration carboplatin chemotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma showeddeep and durable responses, according to the results from Cohort 5 of the phase Ib/II OrigAMI-4 study.

October 30, 2026

Vol.52 No.40

Clinical Roundup

Earlier survivorship care linked to lower risk of head and neck cancer recurrence and death

Beginning survivorship care for head and neck cancer patients earlier is linked to better survival and lower recurrence, according to the findings of a study led by researchers at the University of Pittsburgh.

October 30, 2026

Vol.52 No.40

Clinical Roundup

Johns Hopkins investigators identify a metabolic weak point in exhausted immune cells in head and neck cancer

Immune cells can reach head and neck tumors, but once there, many stop functioning. This helps explain why immunotherapy with immune checkpoint inhibitors—which have transformed treatment for some cancers—benefit only 17% to 23% of patients with head and neck squamous cell carcinoma.

October 02, 2026

Vol.52 No.36

Clinical Guest Editorial

Like it or not, AI psycho-oncology care is already happening. Urgently needed: An ethical framework
Developers and mental health providers must share the same goal: Safe, equitable, trustworthy, and patient-centered care

In 2026, more than 900 million people are estimated to be regularly using generative artificial intelligence—computer systems capable of creating human-like text, images, audio, video, and other original content. AI is becoming integrated into nearly every aspect of daily life. Health care is no exception.

August 14, 2026

Vol.52 No.32

By Viktor Clark, Sean M. Dozier, AnnaLynn M. Williams, Cynthia M. Rand and Lee A. Kehoe

Regulatory News

FDA final guidance on psychedelics opens the door to psycho-oncology research
Guidance permits treatment without psychotherapy, alarming scientists, advocates

FDA has released a final guidance for drug sponsors conducting clinical trials of psychedelics, including psilocybin, LSD, and MDMA, for the treatment of psychiatric and substance abuse disorders.

Rybrevant Faspro + immunotherapy shows strong clinical benefit for recurrent or metastatic head-and-neck cancer

Data from the phase Ib/II OrigAMI-4 study found that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination with a PD-1 inhibitor delivered clinically meaningful and durable antitumor activity in patients with head and neck squamous cell carcinoma that is recurrent or metastatic, PD-L1-positive, and HPV-unrelated.

February 27, 2026

Vol.52 No.08

Brief cognitive behavioral therapy appears promising for head and neck cancer survivors with body-image distress

YOU MAY BE INTERESTED IN

Rybrevant Faspro combination demonstrates 77% ORR in first-line treatment of advanced head and neck cancer, phase II study finds

Earlier survivorship care linked to lower risk of head and neck cancer recurrence and death

Johns Hopkins investigators identify a metabolic weak point in exhausted immune cells in head and neck cancer

Like it or not, AI psycho-oncology care is already happening. Urgently needed: An ethical framework
Developers and mental health providers must share the same goal: Safe, equitable, trustworthy, and patient-centered care

FDA final guidance on psychedelics opens the door to psycho-oncology research
Guidance permits treatment without psychotherapy, alarming scientists, advocates

Rybrevant Faspro + immunotherapy shows strong clinical benefit for recurrent or metastatic head-and-neck cancer

Renew today!

Subscriber content

Never miss an issue!

Login

Brief cognitive behavioral therapy appears promising for head and neck cancer survivors with body-image distress

YOU MAY BE INTERESTED IN

Rybrevant Faspro combination demonstrates 77% ORR in first-line treatment of advanced head and neck cancer, phase II study finds

Earlier survivorship care linked to lower risk of head and neck cancer recurrence and death

Johns Hopkins investigators identify a metabolic weak point in exhausted immune cells in head and neck cancer

Like it or not, AI psycho-oncology care is already happening. Urgently needed: An ethical frameworkDevelopers and mental health providers must share the same goal: Safe, equitable, trustworthy, and patient-centered care

FDA final guidance on psychedelics opens the door to psycho-oncology researchGuidance permits treatment without psychotherapy, alarming scientists, advocates

Rybrevant Faspro + immunotherapy shows strong clinical benefit for recurrent or metastatic head-and-neck cancer

Never miss an issue!

Login

Like it or not, AI psycho-oncology care is already happening. Urgently needed: An ethical framework
Developers and mental health providers must share the same goal: Safe, equitable, trustworthy, and patient-centered care

FDA final guidance on psychedelics opens the door to psycho-oncology research
Guidance permits treatment without psychotherapy, alarming scientists, advocates